SciSparc Ltd. (SPRC) stock

SPRCNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 3/30

$0.35−0.00 (-0.62%)

Close on Nov 13, 2026Market cap $129.04KP/E 0.0Yield –

SciSparc price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

SciSparc's price to sales ratio was 0.1× on Nov 11, 2026, against 0.9× a year earlier. Over the last 4 years it ranged from 0.0× to 4.2×, with a median of 0.7×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	0.1×	−0.5
2025	Dec 31, 2025	0.6×	+0.1
2024	Dec 31, 2024	0.4×	−0.6
2023	Dec 29, 2023	1.0×	–

Where these numbers come from

Parsed from the XBRL in SciSparc's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-9 reverse split on Mar 4, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SPRC.

Compare: SPRC vs XTLB · SPRC vs RFL · SPRC vs SPRB · SPRC vs CANF · SPRC vs MNOV

Operating margin-978.3% · median -2527.4%

Net margin-1422.8% · median -2258.9%

Company	Revenue	Growth
MNOV	$935.72K	–
RFL	$874.00K	-4.7%
SPRC	$856.00K	-34.5%
XTLB	–	–
SPRB	–	–
CANF	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 3
Held by institutions: 0.0%
Auditor: Brightman Almagor Zohar & Co.
SEC CIK: 1611746

Advertisement
300 × 250

See a number that looks wrong?

SciSparc price to sales ratio

Price to Sales Ratio at the end of each year

More SciSparc figures